A recent study suggested that exosomes can transfer wild-type EGFR, which, upon internalization by EGFR-mutated cancer cells, activates downstream PI3K/AKT and MAPK signaling pathways, thereby conferring osimertinib resistance to EGFR-mutated sensitive cancer cells both in vitro and in vivo[114]. Here, AKT1 is linked to cancer.